Back

A genetic signature predicts aggressive paraganglioma sensitivity to dual PI3K-CDK4/6 inhibition therapy

Karna, B.; Gentile, F.; Gulde, S.; De Martino, D.; Maurer, J.; Ganesan, K.; Wang, K.; Bechmann, N.; Rapizzi, E.; Robledo, M.; Arroba, E.; Herzig, S.; Noelting, S.; Mohr, H.; Pellegata, N. S.

2025-02-23 cancer biology
10.1101/2025.02.18.638668 bioRxiv
Show abstract

Effective medical therapies for metastatic paraganglioma (mPPGL) are currently lacking, leading to dismal prognosis. Building on our knowledge of molecular mechanisms driving PPGL progression, we assessed the therapeutic potential of targeting two critical processes: PI3K signaling and cell cycle regulation. The efficacy of buparlisib (PI3Ki) and ribociclib (CDK4/6i), individually and combined, was assessed in vitro using PPGL cell lines, rat- and patient-derived primary cells, and in vivo using PPGL cells-derived mouse xenografts. The combination therapy demonstrated superior antitumor activity compared to single agents, particularly in vivo. Mechanistically, the efficacy of the combination therapy was associated to the downregulation of FOXM1-controlled genes implicated in mitotic spindle assembly and chromosomal segregation, leading to mitotic catastrophe. Data mining and qRT-PCR showed this genetic signature to be upregulated in human mPPGLs. This suggests that aggressive PPGLs exhibit heightened vulnerability to dual PI3K and CDK4/6 inhibition, offering a promising therapeutic avenue for these challenging cancers.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Oncogene
○ 85 papers in training set
Top 0.1%
10.5%
Similar papers in this journal
2
Cell Death & Disease
147 papers in training set
Top 0.1%
9.7%
3
Molecular Oncology
○ 55 papers in training set
Top 0.1%
7.8%
Similar papers in this journal
4
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.1%
5.5%
Similar papers in this journal
5
Cancer Research
● 130 papers in training set
Top 0.7%
5.1%
Similar papers in this journal
6
Nature Communications
○ 5641 papers in training set
Top 28%
5.1%
7
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.2%
4.8%
8
Cancers
○ 213 papers in training set
Top 1%
4.4%
50% of probability mass above
9
Journal of Experimental & Clinical Cancer Research
○ 25 papers in training set
Top 0.2%
2.6%
10
Cancer Letters
○ 35 papers in training set
Top 0.4%
2.4%
11
eLife
● 5828 papers in training set
Top 46%
2.1%
12
Science Advances
● 1243 papers in training set
Top 21%
1.7%
13
Cells
○ 249 papers in training set
Top 3%
1.7%
14
Communications Biology
○ 993 papers in training set
Top 17%
1.5%
15
Frontiers in Oncology
○ 103 papers in training set
Top 2%
1.5%
16
Cell Reports
○ 1498 papers in training set
Top 20%
1.5%
17
Neoplasia
○ 23 papers in training set
Top 0.4%
1.3%
18
British Journal of Cancer
○ 49 papers in training set
Top 0.9%
1.3%
19
Journal of Clinical Investigation
● 179 papers in training set
Top 4%
1.1%
20
Translational Oncology
○ 21 papers in training set
Top 0.6%
1.1%
21
Clinical Cancer Research
● 64 papers in training set
Top 2%
1.1%
22
iScience
○ 1154 papers in training set
Top 27%
1.1%
23
Cell Communication and Signaling
○ 51 papers in training set
Top 0.8%
1.1%
24
Scientific Reports
○ 3612 papers in training set
Top 68%
1.0%
25
Neuro-Oncology
◐ 36 papers in training set
Top 0.5%
1.0%
26
npj Precision Oncology
○ 53 papers in training set
Top 2%
1.0%
27
Cell Death Discovery
○ 58 papers in training set
Top 1%
0.8%
28
Cell Reports Medicine
○ 153 papers in training set
Top 5%
0.8%
29
JCI Insight
● 277 papers in training set
Top 8%
0.8%
30
Clinical and Translational Medicine
○ 31 papers in training set
Top 0.9%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.